Pioneer of Eph biology and therapeutics: Martin Lackmann (1956–2014)

References

• Atapattu L, Saha N, Llerena C, Vail ME, Scott AM, Nikolov DB, Lackmann M, Janes PW. 2012. Antibodies binding the ADAM10 substrate recognition domain inhibit Eph function. J Cell Sci 125:6084–6093
   PubMed Web of Science ®Google Scholar
• Boyd AW, Lackmann M. 2001. Signals from Eph and ephrin proteins: A developmental tool kit. Sci STKE 112:re20
   Google Scholar
• Boyd AW, Bartlett PF, Lackmann M. 2014. Therapeutic targeting of Eph receptors and their ligands. Nat Rev Drug Discov 13:39–62
   Google Scholar
• Cornish CJ, Devery JM, Poronnik P, Lackmann M, Cook DI, Geczy CL. 1996. S100 protein CP-10 stimulates myeloid cell chemotaxis without activation. J Cell Physiol 166:427–437
   PubMedGoogle Scholar
• Coulthard MG, Morgan M, Woodruff TM, Arumugam TV, Taylor SM, Carpenter TC, Lackmann M, Boyd AW. 2012. Eph/ephrin signaling in injury and inflammation. Am J Pathol 181:1493–1503
   PubMed Web of Science ®Google Scholar
• Day B, To C, Himanen JP, Smith FM, Nikolov DB, Boyd AW, Lackmann M. 2005. Three distinct molecular surfaces in ephrin-A5 are essential for a functional interaction with EphA3. J Biol Chem 280:26526–26532
   PubMedGoogle Scholar
• Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, et al. 2013. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell 23:238–248
   PubMed Web of Science ®Google Scholar
• Garber K. 2010. Of Ephs and ephrins: Companies target guidance molecules in cancer. J Natl Cancer Inst 102:1692–1694
   Google Scholar
• Himanen JP, Rajashankar KR, Lackmann M, Cowan CA, Henkemeyer M, Nikolov DB. 2001. Crystal structure of an Eph receptor-ephrin complex. Nature 414:933–938
   PubMed Web of Science ®Google Scholar
• Himanen JP, Chumley MJ, Lackmann M, Li C, Barton WA, Jeffrey PD, Vearing C, et al. 2004. Repelling class discrimination: Ephrin-A5 binds to and activates EphB2 receptor signaling. Nat Neurosci 7:501–509
   PubMed Web of Science ®Google Scholar
• Himanen JP, Yermekbayeva L, Janes PW, Walker JR, Xu K, Atapattu L, Rajashankar KR, et al. 2010. Architecture of Eph receptor clusters. Proc Natl Acad Sci USA 107:10860–10865
   PubMedGoogle Scholar
• Janes PW, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, Nievergall E, Blobel CP, et al. 2005. Adam meets Eph: An ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123:291–304
   PubMed Web of Science ®Google Scholar
• Janes P, Adikari S, Lackmann M. 2008. Eph/ephrin signaling and function in oncogenesis: Lessons from embryonic development. Curr Cancer Drug Targets 8:473–479
   PubMed Web of Science ®Google Scholar
• Janes PW, Wimmer-Kleikamp SH, Frangakis AS, Treble K, Griesshaber B, Sabet O, Grabenbauer M, et al. 2009. Cytoplasmic relaxation of active Eph controls ephrin shedding by ADAM10. PLoS Biol 7:e1000215
   Google Scholar
• Janes PW, Griesshaber B, Atapattu L, Nievergall E, Hii LL, Mensinga A, Chheang C, et al. 2011. Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors. J Cell Biol 195:1033–1045
   Google Scholar
• Janes PW, Nievergall E, Lackmann M. 2012. Concepts and consequences of Eph receptor clustering. Semin Cell Dev Biol 23:43–50
   PubMed Web of Science ®Google Scholar
• Lackmann M, Boyd AW. 2008. Eph, a protein family coming of age: More confusion, insight, or complexity? Sci Signal 1:re2
   PubMed Web of Science ®Google Scholar
• Lackmann M, Cornish CJ, Simpson RJ, Moritz RL, Geczy CL. 1992. Purification and structural analysis of a murine chemotactic cytokine (CP-10) with sequence homology to S100 proteins. J Biol Chem 267:7499–7504
   PubMed Web of Science ®Google Scholar
• Lackmann M, Rajasekariah P, Iismaa SE, Jones G, Cornish CJ, Hu S, Simpson RJ, et al. 1993. Identification of a chemotactic domain of the pro-inflammatory S100 protein CP-10. J Immunol 150:2981–2991
   PubMed Web of Science ®Google Scholar
• Lackmann M, Bucci T, Mann RJ, Kravets LA, Viney E, Smith F, Moritz RL, et al. 1996. Purification of a ligand for the Eph-like receptor HEK using a biosensor-based affinity detection approach. Proc Natl Acad Sci USA 93:2523–2527
   PubMedGoogle Scholar
• Lackmann M, Mann RJ, Kravets L, Smith FM, Bucci TA, Maxwell KF, Howlett GJ, et al. 1997. Ligand for Eph-related kinase (LERK) 7 is the preferred high affinity ligand for the HEK receptor. J BiolChem 272:16521–16530
   PubMedGoogle Scholar
• Lackmann M, Oates AC, Dottori M, Smith FM, Do C, Power M, Kravets L, Boyd AW. 1998. Distinct subdomains of the EphA3 receptor mediate ligand binding and receptor dimerization. J Biol Chem 273:20228–20237
   PubMedGoogle Scholar
• Nievergall E, Janes PW, Stegmayer C, Vail ME, Haj FG, Teng SW, Neel BG, et al. 2010. PTP1B regulates Eph receptor function and trafficking. J Cell Biol 191:1189–1203
   PubMedGoogle Scholar
• Nievergall E, Saunders T, Lackmann M. 2012. Targeting Eph receptor kinases for cancer therapy. Crit Rev Oncog 17:211–232
   PubMedGoogle Scholar
• Nikolov DB, Li C, Lackmann M, Jeffrey P, Himanen JP. 2007. Crystal structure of the human ephrin-A5 ectodomain. Prot Sci 16:996–1000
   Google Scholar
• Oates AC, Lackmann M, Power MA, Brennan C, Down LM, Do C, Evans B, et al. 1999. An early developmental role for Eph–ephrin interaction during vertebrate gastrulation. Mech Dev 83:77–94
   PubMedGoogle Scholar
• Smith FM, Vearing C, Lackmann M, Treutlein H, Himanen J, Chen K, Saul A, et al. 2004. Dissecting the EphA3/ephrin-A5 interactions using a novel functional mutagenesis screen. J Biol Chem 279:9522–9531
   PubMedGoogle Scholar
• Vail ME, Murone C, Tan A, Hii L, Abebe D, Janes P, Lee FT, et al. 2014. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Cancer Res 74:4470–4481
   PubMed Web of Science ®Google Scholar
• Vearing C, Lee FT, Wimmer-Kleikamp S, Spirkoska V, To C, Stylianou C, Spanevello M, et al. 2005. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: Potential as EphA3-specific tumor-targeting reagents. Cancer Res 65:6745–6754
   PubMedGoogle Scholar
• Wimmer-Kleikamp SH, Janes PW, Squire A, Bastiaens PI, Lackmann M. 2004. Recruitment of Eph receptors into signaling clusters does not require ephrin contact. J Cell Biol 164:661–666
   PubMedGoogle Scholar
• Wimmer-Kleikamp SH, Nievergall E, Gegenbauer K, Adikari S, Mansour M, Yeadon T, Boyd AW, et al. 2008. Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells. Blood 112:721–732
   PubMedGoogle Scholar